Showing results (181-190 of 322) with videos related to
Sort By:
Pageof 33
The Korean Journal of Hematology|April 6, 2012
A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomasJeong Eun Kim, Dok Hyun Yoon, Geundoo Jang, et al.Journal of Clinical Apheresis|September 21, 2007
A randomized comparison of peripheral blood hematopoietic progenitor cell level of 5/mm3 versus 50/mm3 as a surrogate marker to initiate efficient autologous blood stem cell collectionMin Kyoung Kim, Shin Kim, Geundoo Jang, et al.Cancer|November 12, 2009
Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancerDae Ho Lee, Sang-We Kim, Cheolwon Suh, et al.Annals of Hematology|July 21, 2017
Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabineJae-Cheol Jo, Dok Hyun Yoon, Shin Kim, et al.The Korean Journal of Internal Medicine|November 4, 2016
Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working PartyYong Park, Byung Bae Park, Ji Yun Jeong, et al.Investigational New Drugs|May 8, 2009
Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trialSung Yong Oh, Won Seog Kim, Dae Ho Lee, et al.Transfusion|March 27, 2004
Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed dosesCheolwon Suh, Hyo-Jung Kim, Sang-Hee Kim, et al.Annals of Hematology|October 21, 2010
Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemmaSeok Jin Kim, Sung Yong Oh, Jin Seok Kim, et al.Oncotarget|September 24, 2017
The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myelomaJin Roh, Youkyoung Jeon, A-Neum Lee, et al.International Journal of Hematology|October 7, 2018
Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasoneJunghoon Shin, Je-Jung Lee, Kihyun Kim, et al.Pageof 33